KOL Insight - Wet Age-related Macular Degeneration

This report delves into the evolving landscape of wet age-related macular degeneration (wAMD) treatment, offering a comprehensive analysis based on insights from key opinion leaders (KOLs) across the USA and Europe. It provides an in-depth examination of both current and pipeline therapies, highlighting the advantages and limitations of existing treatments such as Eylea HD, Vabysmo, and Avastin, as well as emerging therapies like Axpaxli and OPT-302. The report explores the potential impact of new developments, including at-home optical coherence tomography (OCT) and gene therapies, on treatment paradigms. It also addresses the challenges and unmet needs in wAMD management, offering a forward-looking perspective on how the treatment landscape is expected to evolve over the next 3-5 years.

Key Questions Answered:

• 1. What treatments currently form the backbone of wet age-related macular degeneration (wAMD) therapy?
• 2. What are the advantages and disadvantages of current wAMD treatments?
• 3. What are the current unmet needs and challenges in treating wAMD?
• 4. Which products are currently in the development pipeline for wAMD?
• 5. How are pipeline therapies expected to impact treatment pathways for wAMD?
• 6. How is the treatment landscape for wAMD expected to evolve over the next 3-5 years?

Key Brands:

Partial List of Participating Experts:

• Consultant ophthalmic and retinal surgeon at the London Clinic and the Guthrie Clinic at Kings College Hospital, and Professor of retinal research at Kings College London, London, UK
• Professor of Ophthalmology, University Hospital of Bordeaux, Bordeaux, France
• Head of the Medical retina and imaging unit, Associate Professor of Ophthalmology at Universita Vita-Salute San Raffaele, Milan, Italy
• Director of artificial intelligence and imaging research, Doheny Eye Institute and Professor of Ophthalmology at the University of California- Los Angeles, USA
• Professor of Ophthalmology and Neuroscience at John Hopkins Wilmer eye institute
• Professor and Interim medical professor of the Hietzing clinic, Vienna, Austria

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.